Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD |
- 1.50 CDE
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
|
Enduring |
|
$0.00 |
Ace the Case Challenge Series: The Intersection of MASH and Cardiometabolic Risk |
- 0.50 CDE
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |
The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes |
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |
The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes |
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |